PathAI
AI-powered pathology platform to improve patient outcomes through precision diagnostics
Enterprise·Technical·Powered by PathAI (proprietary)·API available
Key strengths
AI-powered pathology algorithmsLarge proprietary pathologist contributor network (450+ board-certified pathologists)Extensive annotation dataset (32.5M+ annotations)FDA-cleared digital pathology platform (AISight® Dx)CE-IVDR marked platformBiomarker discovery and drug development supportCloud-native open platform enterprise workflow (AISight®)
Enterprise pricing
Boston, USA
Founded 2016
Facts verified against pathai.com on
Get alerts when PathAI changes
Free. We'll email you when pricing, the free tier, API access or open-source status changes.
No ratings yet
PathAI – Technical Use Cases
- Clinical Deployment of AI Pathology Algorithms: Institutions can deploy FDA-cleared AI algorithms via AISight® Dx within compliant clinical workflows, supporting diagnostic decision-making in anatomic pathology.
- Enterprise Workflow Integration: AISight®'s cloud-native, open architecture enables academic medical centers, reference laboratories, and health systems to integrate AI pathology tools into existing LIS/digital pathology infrastructure.
- Multi-Algorithm Environments: Via integrations with Deep Bio, Paige, Visiopharm, and DoMore Diagnostics, technical teams can orchestrate multiple third-party AI algorithms within a single platform environment.
- BioPharma Drug Development & Biomarker Discovery: PathAI's annotation dataset and AI algorithms can be applied to computational pathology pipelines supporting biomarker identification, patient stratification, and clinical trial tissue analysis.
- Large-Scale Annotation & Model Training: The 32.5M+ annotation corpus and 450+ pathologist contributor network represent infrastructure that BioPharma and research teams can leverage for AI model development and validation.
Alternatives
See all alternatives Alternatives to PathAI
Is PathAI yours? Claim the listing & get the badge